Final Agenda (pdf)
DownloadDay 1
CCALC FDA Dialogue Session 2023 Welcome_Beatriz Rocha-Dominic Chiapperino (pdf)
DownloadTopic 1 Translation and Discordant Findings_Silvia Calderon (pdf)
DownloadTopic 2 HAP Selecting Margins for Different Positive Controls_Denise Milovan (pdf)
DownloadTopic 2 Enhancement HAP population_Ling Chen (pdf)
DownloadTopic 3 Challenges with Adverse Events_Cindi Arons (pdf)
DownloadTopic 3 AEs and Analysis_Steven Galati FDA (pdf)
DownloadTopic 4 Behavioral Economics for Abuse Liability Testing_Neil Varshneya (pdf)
DownloadTopic 4 Behavioral Economics_Steven Hursh (pdf)
DownloadTopic 5 Abuse Assessment of Psychedelics_Katherine Bonson (pdf)
DownloadTopic 5 Clinical Considerations for Psychedelic HAP Studies_Beatrice Setnik (pdf)
DownloadDay 2
Topic 6 Nonclinical PDW Assessment_Jovita Randall-Thompson (pdf)
DownloadTopic 6 Physical Dependence_Tom Hudzik (pdf)
DownloadTopic 6 Clinical PDW Assessments_Emily Deng (pdf)
DownloadTopic 6 Pragmatic Considerations in Assessing Physical Withdrawal_Thomas Sciascia (pdf)
DownloadTopic 7 Preclinical Evaluations_Sharon Rowton (pdf)
DownloadTopic 7 Preclinical methods_Chad Reissig (pdf)
DownloadTopic 7 Study Design_Anton Bespalov-Tom Hudzik (pdf)
DownloadCopyright © 2024 ADVANCEMENTS AND CHALLENGES IN ABUSE POTENTIAL EVALUATION 2023 - All Rights Reserved.
Powered by GoDaddy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.